Aquatic Capital Management Boosts Position in PTC Therapeutics Amid Analyst Upgrades Aquatic Capital Management LLC has acquired 59,569 shares of PTC Therapeutics, signaling increased institutional interest. Recent analyst reports show a consensus "Moderate Buy" rating, with price targets ranging from $45 to $113. The company’s stock currently trades near $49.53, reflecting cautious optimism despite recent volatility.12